Faecal calprotectin in suspected paediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 3, 2015, Pages 339-346

  Degraeuwe, Pieter L J ^a   Beld, Monique P A ^a   Ashorn, Merja ^b   Canani, Roberto Berni ^c   Day, Andrew S ^d   Diamanti, Antonella ^e   Fagerberg, Ulrika L ^f   Henderson, Paul ^g   Kolho, Kaija Leena ^h   Van De Vijver, Els ⁱ   Van Rheenen, Patrick F ^j   Wilson, David C ^g   Kessels, Alfons G H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f Västmanlands Hospital   (Sweden)

^g Department of Paediatric Gastroenterology and Nutrition Royal Hospital for Sick Children   (Finland)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

adolescent; child; infant; inflammatory bowel diseases; leukocyte L1 antigen complex; meta analysis

Indexed keywords

CALGRANULIN; FAECAL CALPROTECTIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; FALSE NEGATIVE RESULT; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADOLESCENT; CHEMISTRY; CHILD; COHORT ANALYSIS; FECES; INFANT; INFLAMMATORY BOWEL DISEASES; METABOLISM; PERSONALIZED MEDICINE; RISK; STATISTICAL MODEL;

ADOLESCENT; BIOMARKERS; CHILD; COHORT STUDIES; FECES; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; LOGISTIC MODELS; PRECISION MEDICINE; RISK; SENSITIVITY AND SPECIFICITY;

EID: 84926317154     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000615     Document Type: Article

References (50)

1. Timmer A, Behrens R, Buderus S, et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-Language Pediatric Inflammatory Bowel Disease Registry. J Pediatr 2011; 158: 467-73
2. Levine A, Koletzko S, Turner D, et al. ESPGHAN Revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806
3. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-34
4. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-13
5. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-Analysis. BMJ 2010; 341: c3369
6. Riley RD, Dodd SR, Craig JV, et al. Meta-Analysis of diagnostic test studies using individual patient data and aggregate data. Stat Med 2008; 27: 6111-36
7. Lyman GH, Kuderer NM. The strengths and limitations of metaanalyses based on aggregate data. BMC Med Res Methodol 2005; 5: 14
8. Code of Conduct for Medical Research of the Dutch Federation of Biomedical Scientific Societies. http://www.federa.org/sites/default/.files/bijlagen/coreon/code-of-conduct-for-medical-research-1.pdf. Accessed October 10, 2012
9. The University of York Centre for Reviews and Dissemination. http://.www.crd.york.ac.uk/crdweb. Accessed April 1, 2012
10. The Medion Database. www.mediondatabase.nl. Accessed April 1, 2012
11. Doust JA, Pietrzak E, Sanders S, et al. Identifying studies for systematic reviews of diagnostic tests was difficult due to the poor sensitivity and precision of methodologic filters and the lack of information in the abstract. J Clin Epidemiol 2005; 58: 444-9
12. Leeflang MM, Scholten RJ, Rutjes AW, et al. Use of methodological search filters to identify diagnostic accuracy studies can lead to the omission of relevant studies. J Clin Epidemiol 2006; 59: 234-40
13. Lijmer JG, MolBW, Heisterkamp S, et al. Empirical evidence of designrelated bias in studies of diagnostic tests. JAMA 1999; 282: 1061-6
14. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9
15. MIDAS: Stata module for meta-Analytical integration of diagnostic test accuracy studies [computer program]. Boston College Department of Economics; 2009/02/05/.
16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-60
17. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-93
18. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 199-205
19. Berni Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006; 42: 9-15
20. Diamanti A, Panetta F, Basso MS, et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis 2010; 16: 1926-30
21. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-5
22. Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107: 941-9
23. Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 720-5
24. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008; 14: 359-66
25. Van De Vijver E, Schreuder AB, Muller-Kobold AC, et al. Safely ruling out IBD in children and teenagers without referral for endoscopy. Arch Dis Child 2012; 97: 1014-8
26. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-2007, showing increased incidence in Crohn's disease. Scand J Gastroenterol 2009; 44: 446-56
27. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Ann Intern Med 2003; 138: 40-4
28. Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of Intervention. The Cochrane Collaboration; 2011
29. Willis BH, Quigley M. Uptake of newer methodological developments and the deployment of meta-Analysis in diagnostic test research: a systematic review. BMC Med Res Methodol 2011; 11: 27
30. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008; 149: 889-97
31. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006; 332: 1080
32. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002; 91: 45-50
33. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002; 34: 323-4
34. Bachmann LM, Puhan MA, ter Riet G, et al. Sample sizes of studies on diagnostic accuracy: literature survey. BMJ 2006; 332: 1127-9
35. Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol 2005; 58: 859-62
36. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22
37. Anderson BJ, Merry AF. Data sharing for pharmacokinetic studies. Paediatr Anaesth 2009; 19: 1005-10
38. Fischer BA, Zigmond MJ. The essential nature of sharing in science. Sci Eng Ethics 2010; 16: 783-99
39. Hrynaszkiewicz I, Norton ML, Vickers AJ, et al. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ 2010; 340: c181
40. Terry SF, Terry PF. Power to the people: participant ownership of clinical trial data. Sci Transl Med 2011; 3: 69cm3
41. Vickers AJ. Making raw data more widely available. BMJ 2011; 342: d2323
42. Walport M, Brest P. Sharing research data to improve public health. Lancet 2011; 377: 537-9
43. Irwig L, Macaskill P, Glasziou P, et al. Meta-Analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995; 48: 119-30
44. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 2008; 54: 1101-3
45. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-Analyses of drug trials: reanalysis of meta-Analyses. BMJ 2012; 344: d7202
46. Greg Miller W, Myers GL, Lou Gantzer M, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011; 57: 1108-17
47. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010; 56: 714-22
48. Klee GG, Schryver PG, Kisabeth RM. Analytic bias specifications based on the analysis of effects on performance of medical guidelines. Scand J Clin Lab Invest 1999; 59: 509-12
49. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817.e2-26.e2
50. van Schaik FDM, Oldenburg B, Hart AR, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013; 62: 683-8